Skip to main content
Figure 3 | Breast Cancer Research

Figure 3

From: Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice

Figure 3

Poly IC as a mono-adjuvant for strong and broad HER2-specific CD4+ T-cell responses. C57BL/6 (A), BALB/c (B), or FVB/N (C) mice were primed with 5 μg of DEC-HER2 + 50 μg of poly IC and boosted 4 weeks later. Two weeks after the boost, HER2-specific IFNγ production was quantified by enzyme-linked immunosorbent spot assay. All experiments were performed with at least three mice per group, and the results of one of two or three independent experiments are shown. (D) Requirement for DEC expression. DEC-/- or wild-type C57BL/6 mice were primed and boosted 4 weeks apart with DEC-HER2 + poly IC, Ctrl Ig-HER2 + poly IC, or nothing. Two weeks after the boost, splenocytes were harvested and re-stimulated with medium alone or 2 μg/mL HIV gag or HER2 peptide pool 5 for 6 hours. IFNγ production was measured by intracellular cytokine staining. Fluorescence-activated cell sorting blots are shown. Three or four mice were in each group, and the results of one of two experiments are shown. (E) Requirement for pattern recognition receptors. Wild-type, TLR3 KO, or TLR3/MDA5 DKO C57BL/6 mice were immunized with DEC-HER2 + poly IC. Two weeks after the boost vaccination, splenocytes were harvested and re-stimulated with medium alone or 2 μg/mL HIV gag or HER2 peptide pool 5 for 6 hours. IFNγ production was measured by intracellular cytokine staining. Three mice were in each group. ***P < 0.001. HER, human epidermal growth factor receptor; IFNγ, interferon-gamma; Ig, immunoglobulin; poly IC, polyinosinic/polycytidylic acid; TLR, Toll-like receptor.

Back to article page